coronavirus

Core revenues were up 10 percent organically, while COVID-19 testing contributed $535 million to revenues in Q1 2021.

The firm said its rapid antigen test provided 97.3 percent sensitivity and 99.6 percent specificity in clinical studies, and it is developing a saliva-based version.

This modular system uses a high-throughput version of the company's Applied Biosystems TaqPath COVID-19 Combo Kit, which received an EUA in March 2020.

The test, which runs on Ortho's Vitros system, was first CE marked in October for use with nasopharyngeal swab specimens and certain viral transport media.

The company is planning to fund projects for SARS-CoV-2 testing, early disease detection, disease prognostics, and public health genomics projects.

Lucira Health's at-home molecular test received Emergency Use Authorization in November for prescription use.

Novacyt noted that it generated $98.5 million in the first quarter of 2021, about half of which came from sales to the DHSC.

Hologic intends to invest in assay development for Mobidiag's Novodiag PCR platform, which provides high-level multiplexing to detect infectious disease organisms.